Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach.

ABSTRACT:

Background

The challenges that remain in the treatment of solid tumors with chimeric antigen receptor (CAR)-T cells include limited solid tumor-specific targets and poor CAR-T cell expansion and function due to limited availability of solid tumor antigens outside the tumor microenvironment. Prostate cancer is the second most common cancer among men worldwide. Current CAR-T therapies for prostate cancer lack specific targets, posing safety risks. To overcome these problems, we identified prostatic acid phosphatase (PAP, also known as ACPP or ACP3) as a feasible CAR-T target for prostate cancer and developed CoupledCAR, a novel approach for expanding tumor-targeting CAR-T cells without tumor antigens.

Methods

We analyzed the expression of PAP from The Cancer Genome Atlas datab

SUBMITTER: Cao Z 

PROVIDER: S-EPMC12161386 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature